Roivant's mosliciguat shows strong efficacy in Phase 2 PH-ILD trial

Roivant's experimental drug mosliciguat achieved strong efficacy signals in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The mid-stage trial met its primary endpoints, indicating the compound can improve key clinical measures in this serious lung condition.

The positive readout suggests mosliciguat could become a new therapeutic option for patients with PH-ILD and may generate a second blockbuster revenue stream for Roivant. Success in this indication would broaden the company's pipeline beyond its existing assets.

The result also highlights Roivant's reputation for strategic dealmaking and innovative drug development. By advancing a candidate from a novel origin, the company demonstrates how its acquisition and partnership model can translate into clinical progress.